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Background: Brain metastasis from epithelial ovarian cancer (EOC) is very rare with a reported incidence of less than
2%. It is usually associated with a poor prognosis that is related to several factors, the most important including:
single vs multiple lesions, performance status, platinum-sensitive disease, tumor grade, extracranial disease, and
multimodal approach treatment. At the time of diagnosis, an extracranial disease is found in over half of patients.
The most common histology is the serous type. The median time from primary diagnosis to development of cerebral
lesions is directly correlated to initial tumor grade and stage. Several therapeutic approaches can be proposed,
including best supportive care +/- corticosteroids, surgery, radiotherapy and chemotherapy. A multimodal therapy
approach may achieve an improved outcome and should therefore be utilized whenever applicable.
Case presentation: We present the case of a patient with a solitary brain metastasis which appeared 11 years after a
locally advanced and aggressive EOC (FIGO stage III C) and which totally regressed after surgery and adjuvant
chemotherapy. Clinically, she showed progressive headaches, decreased visual acuity, balance and memory disorders
associated with a confusional state. Brain CT scan and MRI documented a solitary, necrotic lesion in the left central
parietal region with an important cerebral surrounding edema and initial cranial herniation. No other extracranial
metastases were observed at the PET scan. Laboratory tests were in the normal range and CA 125 was moderatly
increased at 81 UI/ml. The patient underwent surgical removal of tumor lesion, post-surgical whole-brain radiotherapy
(WBRT) and systemic chemotherapy with carboplatin alone for six cycles. At a follow-up of 13 months, she is alive, in
good clinical condition and tumor progression free.
Conclusion: The peculiarity of this case relies on the isolated brain relapse of a BRCA-1/BRCA-2 non-mutated
EOC, which is uncommon and rare, and to the very long time, of 11 years, from diagnosis of primary cancer and
development of brain metastasis. A multimodal, aggressive approach of this isolated brain metastasis led to a complete
and prolonged tumor control.
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Approximately 20–40% of all cancer patients develop
brain metastases with breast cancer, lung cancer and
melanoma representing the most common primary tu-
mors [1]. The reported incidence of brain metastases
from epithelial ovarian cancer (EOC) is less than 2%.
Brain involvement is usually associated with a poor
prognosis [1-3]. Several factors seem to have an impact
on overall survival (OS), including single lesion,* Correspondence: raflongo@libero.it
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grade, extracranial disease, and, probably, multimodal
approach but all these factors have not been evaluated
and validated in prospective studies [4,5]. The standard
treatment consists of whole-brain radiotherapy (WBRT),
which improves the quality of life by a reduction of
neurological symptoms and prolongs OS to 3–6 months
[6]. Patients with a good performance status, a con-
trolled extracranial disease and a single brain lesion are
generally considered for more aggressive therapeutic
strategies, including surgical resection, stereotactic ra-
diosurgery, postoperative radiation, and chemotherapy
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presenting an isolated EOC brain metastasis, 11 years
after the primary tumor treatment.
Case presentation
In Jun 2001, a 51-year-old woman was submitted to rad-
ical surgery followed by 6 cycles of systemic chemother-
apy with a carboplatin/taxol regimen for a FIGO stage
IIIC mixed, undifferentiated and clear-cells ovarian can-
cer. The follow-up was uneventful until July 2012 when
an increase of the tumor marker CA 125 was observed
at 46 UI/ml. A chest-abdomen and pelvic CT scan was
also performed and it was negative. In December 2012,
the patient was hospitalized because of progressive head-
aches, decreased visual acuity, balance and memory dis-
orders associated with a confusional state. Brain CT scan
and MRI documented a solitary, necrotic lesion in the
left central parietal region with an important cerebral
surrounding edema and initial cranial herniationFigure 1 A solitary brain metastasis of epithelial ovarian carcinoma (E
with an important cerebral surrounding edema and initial cranial herniation
lesion (SPECT MRI; red arrow). D: A metastatic poorly differentiated carcinom
cells (Immunohistochemistry).(Figure 1A-B, red arrow). A PET scan was negative. La-
boratory tests were in the normal range and CA 125 was
at 81 UI/ml. The SPECT MRI revealed the absence of
neurological cells in the lesion leading to the hypothesis
of a late, solitary ovarian metastasis (Figure 1C, red
arrow).
A corticosteroid therapy was started with a progressive
improvement of neurologic symptoms. In January 2013
she underwent craniotomy with radical tumor resection.
Histology showed a metastatic poorly differentiated car-
cinoma with an immunohistochemical profile (cytokera-
tin 7/WT1 positive) compatible with metastasis from
ovarian primary (Figure 1D-E). A post-surgery WBRT
has been performed followed by a systemic monoche-
motherapy by carboplatin for six cycles.
A mutational analysis was also performed and it did
not find any mutation of the BRCA1/BRCA2 genes.
At a follow-up of 13 months, the patient is alive,
asymthomatic, in good clinical conditions and tumorOC). A–B: A solitary, necrotic lesion in the left central parietal region
(brain MRI; red arrow). C: Absence of neurological cells in the tumor
a (Histology). E: Cytokeratin 7 and WT1 positivity of tumor
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UI/ml).
Conclusions
Brain metastases from EOC are very uncommon with a
reported incidence in the literature of 1–2.5% [1-3]. This
incidence is probably underestimated because of the fact
that brain imaging is not generally included in routine
follow-up. However, from its first description in 1978 by
Mayer et al. [8], a rise in incidence has been observed
probably reflecting: i) an improvement of imaging tech-
niques, leading to an earlier and more sensitive diagnosis
of brain lesions; ii) a prolonged patients’ survival by a
better therapeutic strategy; iii) biological mechanisms in-
volving the blood–brain barrier (BBB) that can either
lead to an early brain implantation after its potential
chemotherapy-induced imparement or avoid a drug
penetration into the brain acting as a safe haven.
Radiologically, brain involvement is often multiple and
presents a mixed, solid-cystic form [9]. The frontal lobe
is the most frequent localisation [9]. At time of diagno-
sis, an extracranial disease is found in over half of the
patients [1-3].
About 80% of the patients present a FIGO stage III or
IV at the first diagnosis of EOC [2]. The most common
histology is the serous type, which is reported in over
half of the cases, followed by mixed epithelial, endome-
trioid, adenocarcinoma, mucinous, undifferentiated and
clear cell histology, all in decreasing frequency [2].
The reported median time from primary diagnosis to
development of cerebral lesions is variable and directly
correlated to initial tumor grade and stage [10,11].
Only two independent prognostic factors have been
shown to have a relevant clinical impact: i) the presence
of extracranial disease at the time of brain relapse and ii)
the performance status [1]. Conflicting results have
been reported with other potential factors, including
“single” vs “multiple” localisations, the interval time
from primary diagnosis and metastatic manifestation,
tumor stage, grade, histotype, age at diagnosis of brain
relapse, site of lesion, and treatment strategy [4,12].
However, a recent German, multicenter, retrospective
review documented, in a multivariate analysis, five nega-
tive prognostic factors, including performance status,
platinum-sentive disease, tumor grading, FIGO staging,
and presence of multiple vs single lesions. Other factors,
such as histology, age at primary diagnosis, ascites, re-
sidual tumor at primary surgery, extracranial disease at
time of brain relapse, presentation with or without head-
ache did not directly impact on OS. A trend for significatly
longer survival for the multimodal therapy was also
observed [5].
Germlime mutations of BRCA-1 and -2 genes have
been reported in 10% of EOC and they seem to correlatewith a more aggressive behaviour and a metastatic dis-
ease [13]. Recently, several reports showed a strict cor-
relation between BRCA-1 mutations and incidence of
brain metastases in EOC [14,15].
Several therapeutic approaches can be proposed, in-
cluding best supportive care +/- corticosteroids, surgery,
radiotherapy and chemotherapy. When applicable, con-
ventional neurosurgery promises the best results. In case
of contraindications to surgery, inaccessibility of lesions
and the presence of multiple metastases, the most com-
monly used individual therapy strategy is WBRT that
improves neurological symptoms and prolongs median
survival up to 3–6 months [1,6].
The role of systemic chemotherapy is controversial
with a reported median OS up to 16 months even when
combined with surgery or radiation [2,7]. These data
probably reflect the impossibility to reach a high cere-
brospinal fluid drug concentration with the actual cyto-
toxic agents most active in EOC which are unable to
cross the blood–brain barrier.
Several studies have documented an increased thera-
peutic potential by a multimodal, more aggressive
approach.
Cohen et al. reported a median OS of 5.6 months for
surgery or WBRT, when these are employed individually,
and of 23.1 months after a combination of both strat-
egies [6]. The addition of chemotherapy to surgery and
radiotherapy seems to improve OS of 3–6 months but
these data derived from retrospective, small-cohorts
studies and have not been prospectively validated [1,16].
Recently, stereotactic radiotherapy showed promising re-
sults with a remarkable median survival of 29 months as
compared to 6 months with WBRT [17] but it is mostly
applied in selected patients with no more than 3 cerebral
lesions. It is now prospectively evaluating into a multi-
modal approach and also in patients with multiple
lesions.
A multimodal therapy approach may achieve an im-
proved outcome for the patients and should therefore be
used whenever applicable. The evidence available to date
is pointing towards a combination of surgery and radio-
therapy as the treatment modality with the best benefit
to drawback ratio [1]. An additional chemotherapy can
potentially improve clinical outcome in some patients,
but this benefit has to be measured against possible
side-effects. Further research is needed to clarify the
value of chemotherapeutic agents having a potential of
reaching high concentrations in the cerebrospinal fluid.
In our case, the patient presented a solitary brain me-
tastasis 11 years after a locally advanced and aggressive
EOC which totally regressed after surgery and post-
surgical chemotherapy. Brain involvement was associ-
ated with a moderatly increase of tumor marker CA125.
No other extracranial metastases were observed. The
Longo et al. BMC Cancer 2014, 14:543 Page 4 of 4
http://www.biomedcentral.com/1471-2407/14/543patient underwent a multimodal and aggressive treat-
ment, including surgical resection of the tumor lesion,
post-surgical WBRT and systemic chemotherapy with
carboplatin alone for six cycles that led to a complete
and prolonged tumor control.
The peculiarity of this case relies on the isolated brain
relapse of a BRCA-1 and BRCA-2 non-mutated EOC,
which is uncommon and rare, and to the very long time,
of 11 years, from diagnosis of primary cancer and devel-
opment of brain metastasis. Finally, a multimodal and
aggressive approach achiewed a prolonged tumor-free
survival.
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